GlassScriptPhysician profile
Moise Anglade
NPI 1992904718
$11,220.34
in general payments reported to CMS, 2019-2025
25 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,567 · 2020: $1,137 · 2021: $842 · 2022: $643 · 2023: $200 · 2024: $501 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,076.72 | 2019-2025 | Leqvio |
| Abbott Laboratories | $2,089.90 | 2019-2024 | Amplatzer Amulet, Aveir |
| Medtronic Vascular, INC. | $1,690.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $542.68 | 2019-2022 | |
| Boston Scientific Corporation | $259.14 | 2020-2024 | Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $243.22 | 2021-2024 | Cobalt Dr Mri Surescan, Linq II, Reveal Linq |
| Astellas Pharma US INC | $208.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $172.69 | 2019-2025 | Farxiga |
| Biotronik Nro, INC. | $170.37 | 2025 | Prospera |
| Pfizer INC. | $151.46 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $94.78 | 2019-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.34 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $79.73 | 2022 | |
| Novo Nordisk INC | $58.51 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $57.25 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38.47 | 2024 | |
| Cvrx, INC. | $30.80 | 2023 | Barostim Neo System |
| Philips North America LLC | $29.10 | 2022 | |
| Amgen INC. | $25.44 | 2020 | |
| Biotronik INC. | $22.28 | 2019 | |
| Merck Sharp & Dohme LLC | $20.80 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $19.90 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.35 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $17.85 | 2019 | |
| Genzyme Corporation | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moise Anglade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.